Selective inhibition of prostacyclin synthase activity by rofecoxib

The development of cyclooxygenase-2 (COX-2) selective inhibitors prompted studies aimed at treating chronic inflammatory diseases and cancer by using this new generation of drugs.Yet, several recent reports pointed out that long-term treatment of patients with COX-2 selective inhibitors (especially...

Descripción completa

Detalles Bibliográficos
Autores principales: Griffoni, Cristiana, Spisni, Enzo, Strillacci, Antonio, Toni, Mattia, Bachschmid, Markus Michael, Tomasi, Vittorio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2007
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3822831/
https://www.ncbi.nlm.nih.gov/pubmed/17488481
http://dx.doi.org/10.1111/j.1582-4934.2007.00021.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3822831/
https://www.ncbi.nlm.nih.gov/pubmed/17488481
http://dx.doi.org/10.1111/j.1582-4934.2007.00021.x

Ejemplares similares